StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.47−4.16 (-4.26%)

Close on Nov 20, 2026Market cap $8.24BP/E –Yield –

Spyre Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Spyre Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0, down 100.0% year over year. For fiscal 2025 it was $0. The highest annual figure on record is $18.74M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–
FY2024Dec 31, 2024$0-100.0%
FY2023Dec 31, 2023$886.00K-62.0%
FY2022Dec 31, 2022$2.33M-87.6%
FY2021Dec 31, 2021$18.74M–
FY2020Dec 31, 2020$0–
FY2019Dec 31, 2019$0-100.0%
FY2018Dec 31, 2018$3.89M-25.3%
FY2017Dec 31, 2017$5.21M+12.5%
FY2016Dec 31, 2016$4.63M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$688.00K+10.1%
Q1 FY2023Mar 31, 2023$198.00K-85.5%
Q4 FY2022Dec 31, 2022$168.00K-95.4%
Q3 FY2022Sep 30, 2022$174.00K-87.6%
Q2 FY2022Jun 30, 2022$625.00K-95.4%
Q1 FY2022Mar 31, 2022$1.36M–
Q4 FY2021Dec 31, 2021$3.64M–
Q3 FY2021Sep 30, 2021$1.40M–
Q2 FY2021Jun 30, 2021$13.70M–
Q1 FY2021Mar 31, 2021$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0-100.0%
Q1 FY2019Mar 31, 2019$0-100.0%
Q4 FY2018Dec 31, 2018$0-100.0%
Q3 FY2018Sep 30, 2018$0-100.0%
Q2 FY2018Jun 30, 2018$2.38M+60.8%
Q1 FY2018Mar 31, 2018$1.51M+53.8%
Q4 FY2017Dec 31, 2017$1.48M–
Q3 FY2017Sep 30, 2017$1.26M–
Q2 FY2017Jun 30, 2017$1.48M–
Q1 FY2017Mar 31, 2017$982.00K–

More Spyre Therapeutics figures

See a number that looks wrong?